94 research outputs found

    Presumed guilty: how the Jews were blamed for the death of Jesus

    Get PDF
    Title: Presumed guilty: how the Jews were blamed for the death of Jesus. Author: Tomson, Peter J Presumed guilty xiv, 146 p. Publisher: Zoetermeer, Netherlands : Uitgeverij Meinema ; Minneapolis : Fortress, 2005

    Introducing the Bible

    Get PDF
    Title: Introducing the Bible. Author: Drane, John Introducing the Bible 730 p. Publisher: Minneapolis : Fortress Pr, 2005

    The Passion of Gibson: evaluating a recent interpretation of Christ\u27s suffering and death in light of the New Testament

    Get PDF
    Passion of the Christ Publisher: [S.l.] : Icon Film Distribution, 2004

    Talking with the other(s): towards interfaith understanding

    Get PDF

    Intravenous buspirone for the prevention of postoperative nausea and vomiting

    Get PDF
    Rationale: Buspirone, a partial 5HT1A agonist and D2 and D3 antagonist, has shown promising antiemetic efficacy when given parenterally in animal models, but its efficacy for the prevention of postoperative nausea and vomiting (PONV) is unknown. Objective: To study the efficacy and dose-responsiveness of intravenous buspirone for the prevention of PONV. Methods: A randomised, double-blind, placebo-controlled study was performed in adults at moderate to high PONV risk undergoing surgery with a general anaesthetic. Patients were randomised to receive an intravenous dose of buspirone (0.3, 1.0, 2.0, 3.0mg) or placebo at the end of surgery. The primary endpoint was the cumulative 24-h PONV incidence (i.e. any nausea and/or vomiting). Vomiting included retching. Nausea was defined as a score of ≥4 on an 11-point verbal rating scale running from zero (no nausea) to ten (the worst nausea imaginable). Results: A total of 257 patients received the study drug and fulfilled the criteria for inclusion in the primary efficacy and safety analyses. With placebo, the mean 24-h PONV incidence was 49.0% (90% confidence interval [CI] 37.5-60.5%). With buspirone, that incidence ranged from a mean of 40.8% (29.3-52.4%) in the 1mg arm to 58.0% (46.5-69.5%) in the 0.3mg arm (P > 0.05 for all comparisons). There was no difference between placebo and buspirone at any dose for any other efficacy endpoint, nor in the number or severity of adverse events or any other safety measures. Conclusion: We were unable to show that intravenous single-dose buspirone, at the tested dose-range, was effective at preventing PONV in surgical adult patients. The present study emphasises the difficulty in extrapolating from animal models of emesis to clinical efficacy in PON

    TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma

    Get PDF
    Telomerase reverse transcriptase (TERT) promoter mutations were recently shown to drive telomerase activity in various cancer types, including medulloblastoma. However, the clinical and biological implications of TERT mutations in medulloblastoma have not been described. Hence, we sought to describe these mutations and their impact in a subgroup-specific manner. We analyzed the TERT promoter by direct sequencing and genotyping in 466 medulloblastomas. The mutational distributions were determined according to subgroup affiliation, demographics, and clinical, prognostic, and molecular features. Integrated genomics approaches were used to identify specific somatic copy number alterations in TERT promoter-mutated and wild-type tumors. Overall, TERT promoter mutations were identified in 21 % of medulloblastomas. Strikingly, the highest frequencies of TERT mutations were observed in SHH (83 %; 55/66) and WNT (31 %; 4/13) medulloblastomas derived from adult patients. Group 3 and Group 4 harbored this alteration in <5 % of cases and showed no association wit

    Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications

    Get PDF
    This work was supported by a restricted research grant of Bayer AG
    corecore